This Review surveys the NASH clinical trial landscape and the main challenges to drug approval, and discusses new approaches to overcoming these, including innovative trial designs, non-invasive tests and biomarkers.
- Stephen A. Harrison
- Alina M. Allen
- Naim Alkhouri